Quarterly report · Q3
2385.TEDINET S100TEAA
Period2023-07-01 → 2024-03-31
Filed2024-05-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥3.8bn | 2023-07-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥8.1bn | 2022-07-01 → 2023-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥6.6bn | 2022-07-01 → 2023-03-31 | Cons. | Net sales |
| Operating income | −¥560m | 2023-07-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥785m | 2022-07-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | −¥529m | 2023-07-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥727m | 2022-07-01 → 2023-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥785m | 2022-07-01 → 2023-03-31 | Cons. | Ordinary income |
| Profit before tax | −¥529m | 2023-07-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥784m | 2022-07-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥575m | 2023-07-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥452m | 2022-07-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥496m | 2022-07-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥575m | 2023-07-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥500m | 2022-07-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥7.0bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥8.2bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥8.7bn | at 2023-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥641m | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥1.1bn | at 2023-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥6.3bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥7.2bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥7.2bn | at 2023-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.9bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.9bn | at 2023-06-30 | Cons. | Cash and deposits |
| EPS (basic) | ¥-21.96 | 2023-07-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.31 | 2024-01-01 → 2024-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.27 | 2022-07-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥18.97 | 2022-07-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥10.97 | 2023-01-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 90.6% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.6% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.8% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 49
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2024-03-31 | −¥17m |
| Reconciling Itemsreconciling | revenue external | 2023-07-01 → 2024-03-31 | ¥1m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2024-03-31 | −¥19m |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2024-03-31 | −¥225m |
| jpcrp040300-q3r_E05367-000Clinical Evidence Servicereportable segment | revenue | 2023-07-01 → 2024-03-31 | ¥192m |
| jpcrp040300-q3r_E05367-000Clinical Evidence Servicereportable segment | revenue external | 2023-07-01 → 2024-03-31 | ¥192m |
| jpcrp040300-q3r_E05367-000Clinical Evidence Servicereportable segment | segment profit | 2023-07-01 → 2024-03-31 | −¥51m |
| jpcrp040300-q3r_E05367-000Functional Cosmetic Retailingreportable segment | revenue | 2023-07-01 → 2024-03-31 | ¥982m |
| jpcrp040300-q3r_E05367-000Functional Cosmetic Retailingreportable segment | revenue external | 2023-07-01 → 2024-03-31 | ¥982m |
| jpcrp040300-q3r_E05367-000Functional Cosmetic Retailingreportable segment | segment profit | 2023-07-01 → 2024-03-31 | −¥177m |
| jpcrp040300-q3r_E05367-000Functional Food Retailingreportable segment | revenue | 2023-07-01 → 2024-03-31 | ¥1.9bn |
| jpcrp040300-q3r_E05367-000Functional Food Retailingreportable segment | revenue external | 2023-07-01 → 2024-03-31 | ¥1.9bn |
| jpcrp040300-q3r_E05367-000Functional Food Retailingreportable segment | revenue intersegment | 2023-07-01 → 2024-03-31 | ¥6m |
| jpcrp040300-q3r_E05367-000Functional Food Retailingreportable segment | segment profit | 2023-07-01 → 2024-03-31 | −¥184m |
| jpcrp040300-q3r_E05367-000Functional Material Developmentreportable segment | revenue | 2023-07-01 → 2024-03-31 | ¥255m |
| jpcrp040300-q3r_E05367-000Functional Material Developmentreportable segment | revenue external | 2023-07-01 → 2024-03-31 | ¥242m |
| jpcrp040300-q3r_E05367-000Functional Material Developmentreportable segment | revenue intersegment | 2023-07-01 → 2024-03-31 | ¥13m |
| jpcrp040300-q3r_E05367-000Functional Material Developmentreportable segment | segment profit | 2023-07-01 → 2024-03-31 | −¥686,000 |
| jpcrp040300-q3r_E05367-000Health Care Support Servicereportable segment | revenue | 2023-07-01 → 2024-03-31 | ¥490m |
| jpcrp040300-q3r_E05367-000Health Care Support Servicereportable segment | revenue external | 2023-07-01 → 2024-03-31 | ¥490m |
| jpcrp040300-q3r_E05367-000Health Care Support Servicereportable segment | segment profit | 2023-07-01 → 2024-03-31 | ¥78m |
| —segment total | revenue | 2023-07-01 → 2024-03-31 | ¥3.9bn |
| —segment total | revenue external | 2023-07-01 → 2024-03-31 | ¥3.8bn |
| —segment total | revenue intersegment | 2023-07-01 → 2024-03-31 | ¥19m |
| —segment total | segment profit | 2023-07-01 → 2024-03-31 | −¥336m |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2023-03-31 | −¥1m |
| Reconciling Itemsreconciling | revenue external | 2022-07-01 → 2023-03-31 | ¥1m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2023-03-31 | −¥3m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2023-03-31 | −¥226m |
| jpcrp040300-q3r_E05367-000Clinical Evidence Servicereportable segment | revenue | 2022-07-01 → 2023-03-31 | ¥404m |
| jpcrp040300-q3r_E05367-000Clinical Evidence Servicereportable segment | revenue external | 2022-07-01 → 2023-03-31 | ¥404m |
| jpcrp040300-q3r_E05367-000Clinical Evidence Servicereportable segment | segment profit | 2022-07-01 → 2023-03-31 | ¥68m |
| jpcrp040300-q3r_E05367-000Functional Cosmetic Retailingreportable segment | revenue | 2022-07-01 → 2023-03-31 | ¥3.4bn |
| jpcrp040300-q3r_E05367-000Functional Cosmetic Retailingreportable segment | revenue external | 2022-07-01 → 2023-03-31 | ¥3.4bn |
| jpcrp040300-q3r_E05367-000Functional Cosmetic Retailingreportable segment | segment profit | 2022-07-01 → 2023-03-31 | ¥701m |
| jpcrp040300-q3r_E05367-000Functional Food Retailingreportable segment | revenue | 2022-07-01 → 2023-03-31 | ¥1.9bn |
| jpcrp040300-q3r_E05367-000Functional Food Retailingreportable segment | revenue external | 2022-07-01 → 2023-03-31 | ¥1.9bn |
| jpcrp040300-q3r_E05367-000Functional Food Retailingreportable segment | segment profit | 2022-07-01 → 2023-03-31 | ¥115m |
| jpcrp040300-q3r_E05367-000Functional Material Developmentreportable segment | revenue | 2022-07-01 → 2023-03-31 | ¥382m |
| jpcrp040300-q3r_E05367-000Functional Material Developmentreportable segment | revenue external | 2022-07-01 → 2023-03-31 | ¥380m |
| jpcrp040300-q3r_E05367-000Functional Material Developmentreportable segment | revenue intersegment | 2022-07-01 → 2023-03-31 | ¥3m |
| jpcrp040300-q3r_E05367-000Functional Material Developmentreportable segment | segment profit | 2022-07-01 → 2023-03-31 | ¥43m |
| jpcrp040300-q3r_E05367-000Health Care Support Servicereportable segment | revenue | 2022-07-01 → 2023-03-31 | ¥463m |
| jpcrp040300-q3r_E05367-000Health Care Support Servicereportable segment | revenue external | 2022-07-01 → 2023-03-31 | ¥463m |
| jpcrp040300-q3r_E05367-000Health Care Support Servicereportable segment | segment profit | 2022-07-01 → 2023-03-31 | ¥83m |
| —segment total | revenue | 2022-07-01 → 2023-03-31 | ¥6.6bn |
| —segment total | revenue external | 2022-07-01 → 2023-03-31 | ¥6.6bn |
| —segment total | revenue intersegment | 2022-07-01 → 2023-03-31 | ¥3m |
| —segment total | segment profit | 2022-07-01 → 2023-03-31 | ¥1.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 314
| Item | Context | Value | Unit |
|---|---|---|---|
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2023-07-01 | |
| Current period end date | FilingDateInstant | 2024-03-31 | |
| Type of current period | FilingDateInstant | Q3 | |
| Current fiscal year end date | FilingDateInstant | 2024-06-30 | |
| Previous fiscal year start date | FilingDateInstant | 2022-07-01 | |
| Comparative period end date | FilingDateInstant | 2023-03-31 | |
| Previous fiscal year end date | FilingDateInstant | 2023-06-30 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所（グロース市場） | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数100株 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Voting rights (text) | FilingDateInstant | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |